Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potent versus mild topical corticosteroids in children with atopic dermatitis in primary care
2017-001525-40Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- May 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydrocortisone, triamcinolone acetonide and fluticasone propionate in atopic dermatitis (AD) (2 arms), sponsored by Erasmus MC. Primary endpoints: Change in disease severity at 1 week and Change in disease severity at 24 weeks. Started May 2017; status: completed.
02
Drugs
hydrocortisonetriamcinolone acetonidefluticasone propionate
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-001525-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001525-40.